Luke Masterson, PhD

Senior Director at AstraZeneca

Speaker

Luke received his PhD in Pharmaceutical Chemistry from the University of Strathclyde in Glasgow and followed this with positions as a postdoctoral research fellow in the Department of Biological Sciences at Strathclyde University and in the CRUK Gene targeted Cancer Research group at the University of London. In 2004 Luke joined the biotech spin-out company Spirogen as Chemistry team Lead and worked on the development of the Pyrrolobenzodiazepine (PBD) DNA interactive agents as ADC payloads. Luke has over ten years’ experience of leading teams of scientists in the development of ADC linker payloads and has led ADC chemistry projects in collaboration with Genentech, SGEN and ADC Therapeutics, leading companies in the ADC field. When Spirogen became part of Astrazeneca Luke continued as Chemistry Group Leader and is currently a Senior Director within AZ leading the UK Tumour Targeted Delivery (TTD) Chemistry team and is site lead of the TTD site in London.